Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories Inc. Class A

The latest announcement is out from Sabio Holdings ( ($TSE:SBIO) ). Sabio Holdings announced it will release its unaudited fiscal Q3 2025 financial...

Sabio Holdings to Release Q3 2025 Financial Results

Zenas BioPharma, Inc. ( ($ZBIO) ) has released its Q3 earnings. Here is a breakdown of the information Zenas BioPharma, Inc. presented to its inves...

Zenas BioPharma Reports Q3 2025 Financial Results

Jade Biosciences, Inc. ( ($JBIO) ) has released its Q3 earnings. Here is a breakdown of the information Jade Biosciences, Inc. presented to its inv...

Jade Biosciences Advances Autoimmune Therapies

Fortress Biotech Inc (($FBIO)) has held its Q3 earnings call. Read on for the main highlights of the call. Fortress Biotech Inc’s recent earnings c...

Fortress Biotech’s Earnings Call Highlights EMROSI Success

The latest update is out from BioVaxys Technology ( ($TSE:BIOV) ). BioVaxys Technology Corp. has announced a debt settlement transaction with certa...

BioVaxys Announces Debt Settlement to Strengthen Financial Position

In a report released today, Austin Moeller from Canaccord Genuity maintained a Hold rating on Bioceres Crop Solutions, with a price target of $2.25...

Bioceres Crop Solutions (BIOX) Receives a Hold from Canaccord Genuity

The latest update is out from Mindbio Therapeutics Corp. ( ($TSE:MBIO) ). MindBio Therapeutics Corp. announced the results of its Phase 2B clinical...

MindBio Therapeutics Reports Phase 2B Trial Results on Microdosed LSD for Depression

Ibio Inc ( ($IBIO) ) has released its Q1 earnings. Here is a breakdown of the information Ibio Inc presented to its investors. iBio, Inc. is a prec...

iBio, Inc. Reports Q3 2025 Financial Results

An announcement from Bioceres Crop Solutions ( ($BIOX) ) is now available. On November 10, 2025, Bioceres Crop Solutions received an Acceleration N...

Bioceres Crop Solutions Faces Legal Action Over Alleged Defaults

The latest announcement is out from BioVaxys Technology ( ($TSE:BIOV) ). BioVaxys Technology Corp. announced an extension of its non-brokered priva...

BioVaxys Extends Private Placement to Boost Immunotherapy Pipeline

Harvard Bioscience (($HBIO)) has held its Q3 earnings call. Read on for the main highlights of the call. Harvard Bioscience’s recent earnings call ...

Harvard Bioscience’s Earnings Call: Optimism Amid Challenges

Crescent Biopharma, Inc. ( ($CBIO) ) has released its Q3 earnings. Here is a breakdown of the information Crescent Biopharma, Inc. presented to its...

Crescent Biopharma Advances Cancer Therapy Pipeline

Mindbio Therapeutics Corp. ( ($TSE:MBIO) ) just unveiled an announcement. MindBio Therapeutics has successfully completed dosing in its landmark Ph...

MindBio Therapeutics Completes Landmark Phase 2B Microdosing Trial for Depression

The latest update is out from Ibio ( ($IBIO) ). On November 4, 2025, iBio, Inc. announced that it has regained compliance with the Nasdaq Listing R...

iBio Regains Nasdaq Compliance with Bid Price Rule

BTIG analyst Julian Harrison maintained a Buy rating on Jade Biosciences yesterday and set a price target of $28.00. The company’s shares opened to...

Jade Biosciences (JBIO) Receives a Buy from BTIG

BioVersys AG ( ($CH:BIOV) ) has issued an update. BioVersys AG has announced the appointment of Dr. Daniel Ritz as the new Chief Scientific Officer...

BioVersys Appoints Dr. Daniel Ritz as Chief Scientific Officer

Bridgebio Pharma (($BBIO)) has held its Q3 earnings call. Read on for the main highlights of the call. BridgeBio Pharma’s recent earnings call refl...

BridgeBio Pharma’s Earnings Call Highlights Success and Challenges

The latest announcement is out from BioVaxys Technology ( ($TSE:BIOV) ). BioVaxys Technology Corp. has announced an increase in its non-brokered pr...

BioVaxys Upsizes Private Placement to Boost Immunotherapy Pipeline

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on BridgeBio Pharma, with a price target of $98.00. The company’s...

Piper Sandler Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

Bridgebio Pharma ( ($BBIO) ) has released its Q3 earnings. Here is a breakdown of the information Bridgebio Pharma presented to its investors. Brid...

BridgeBio Pharma Reports Strong Q3 2025 Results

The latest announcement is out from BridgeBio Pharma ( ($BBIO) ). BridgeBio Pharma announced positive results from its Phase 3 CALIBRATE study of e...

BridgeBio Pharma Reports Positive Phase 3 Study Results

The latest update is out from BioVaxys Technology ( ($TSE:BIOV) ). BioVaxys Technology Corp. announced the conversion of $125,000 in unsecured conv...

BioVaxys Converts Debentures into Equity, Strengthening Financial Position

Evercore ISI analyst Cory Kasimov maintained a Buy rating on BridgeBio Pharma today and set a price target of $75.00. The company’s shares opened t...

BridgeBio Pharma (BBIO) Receives a Buy from Evercore ISI

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Urogen Pharma (URGN – Research Report), AngioDynamic...

Analysts’ Top Healthcare Picks: Urogen Pharma (URGN), AngioDynamics (ANGO)

Zenas BioPharma, Inc. ( ($ZBIO) ) just unveiled an announcement. On October 27, 2025, Zenas BioPharma announced positive results from its Phase 2 M...

Zenas BioPharma Reports Positive Phase 2 Trial Results

In a report released on October 24, Nicolas Pauillac from Kepler Capital maintained a Buy rating on BB Biotech, with a price target of CHF66.00. Th...

Market Cap	$8.30B	P/E Ratio	31.61
52W High	$373.69	52W Low	$211.43
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	-35.0%	52W Position	64.9%
Overall Score	52	Value Score	50
Quality Score	--	Technical Score	54

EPS Current Est	$10.02	EPS Next Est	$10.36
EPS Growth Est	+3.4%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIO	$316.70	+4.31%	126.65K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIO	$316.70	+4.3%	126.65K
3
4
5
6

BIO

BIO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Bio-Rad Laboratories Inc. Class A Data in Excel

Get Bio-Rad Laboratories Inc. Class A Data in Excel